Login to Your Account

IAS 2017

PARIS – A bird in the hand is worth two in the bush. And in that spirit, the newest research on a wide variety of prevention strategies other than vaccination are being presented at the meeting of the International AIDS Society this week.

more »


Merck & Co. Inc. took cardiovascular disease (CVD) experts – and, perhaps, some of its own decision-makers – by surprise last month when it disclosed that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of its cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, met its primary endpoint by reducing major coronary events (defined as the composite of coronary death, myocardial infarction and coronary revascularization) compared to placebo in patients at risk for cardiac events who were already receiving a regimen to lower low-density lipoprotein, or LDL.

read more »

Our Habitat for All Things Science
Genome therapy promises new blood disease treatments

HONG KONG – In a study led by Australian scientists at University of New South Wales (UNSW), introducing a beneficial natural mutation into blood cells using gene-editing was shown to stimulate production of fetal hemoglobin (Hb), a finding that could lead to a cure for blood diseases.

People with potentially life-threatening blood disorders, such as thalassemia or sickle cell anemia (SCA), have impaired adult Hb, so require life-long treatment with blood transfusions and medications.



Partners in Focus